MedImmune’s Alzheimer’s Antibody Partnership With Axerion Showcases Virtual Neuroscience R&D Operation
This article was originally published in The Pink Sheet Daily
The two companies will work together to optimize and develop preclinical antibodies targeted at blocking amyloid-beta oligomer binding to cellular prion protein.
You may also be interested in...
AstraZeneca is to slash 12% of its workforce in the next three years, as the company forecasts declining revenues in 2012 because of its steep patent cliff, government pricing interventions and R&D pipeline failures.
A second failed efficacy trial, CONCERT, provided the final nail in the coffin for the once-promising treatment for Alzheimer’s disease, serving as a cautionary tale against excessive enthusiasm for early clinical trial results.
Axerion Therapeutics Inc.'s technology aims to block the binding of Amyloid beta to the prion protein PrP-C, a mechanism its scientists say is the toxic trigger behind neuronal death in Alzheimer's disease. Based at Yale University in New Haven, the team found that mice with AB plaques but no PrP-C showed no cognitive impairment. (Also see "Axerion Therapeutics Inc." - Scrip, 1 Jul, 2010.)